Cytarabine and Hepatitis acute - a phase IV clinical study of FDA data

Summary:

Hepatitis acute is reported as a side effect among people who take Cytarabine (cytarabine), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Methotrexate, and have Acute lymphocytic leukemia (all).

The phase IV clinical study analyzes which people have Hepatitis acute when taking Cytarabine. It is created by eHealthMe based on reports of 65,319 people who have side effects when taking Cytarabine from the FDA, and is updated regularly.

What is Cytarabine?

Cytarabine has active ingredients of cytarabine. It is often used in acute myelogenous leukemia (aml) - adult. eHealthMe is studying from 65,358 Cytarabine users. Check the latest studies of Cytarabine.

What is Hepatitis acute?

Hepatitis acute is found to be associated with 596 drugs and 877 conditions by eHealthMe. Check the latest studies of Hepatitis acute.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

65,319 people reported to have side effects when taking Cytarabine.
Among them, 67 people (0.1%) have Hepatitis acute.

Among these 67 people:

How long have people been on Cytarabine when they have Hepatitis acute? *

What is the gender of people who have Hepatitis acute when taking Cytarabine? *

female: 35.48 %
male: 64.52 %

What is the age of people who have Hepatitis acute when taking Cytarabine? *

What are other drugs people take besides Cytarabine? *

What are other side effects people have besides Hepatitis acute? *

Febrile Neutropenia (fever with reduced white blood cells): 25 people, 37.31%
Venoocclusive Liver Disease (small veins in the liver are obstructed): 18 people, 26.87%
Abdominal Pain: 15 people, 22.39%
Weight Increased: 15 people, 22.39%
Hepatomegaly (abnormal enlargement of the liver): 13 people, 19.40%
Hepatic Failure (liver failure): 11 people, 16.42%
Sepsis (a severe blood infection that can lead to organ failure and death): 11 people, 16.42%
Bleeding Disorders: 9 people, 13.43%
Pyogenic Liver Abscess (liver abscess caused by bacteria): 8 people, 11.94%
Encephalopathy (functioning of the brain is affected by some agent or condition): 8 people, 11.94%

What are the existing conditions these people have? *

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 15 people, 22.39%
Bone Marrow Conditioning Regimen: 13 people, 19.40%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 12 people, 17.91%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 9 people, 13.43%
Myeloid Leukaemia (a type of cancer in which the bone marrow makes abnormal myeloblasts): 4 people, 5.97%
Fever: 3 people, 4.48%
Type 2 Diabetes: 2 people, 2.99%
Sciatica (a set of symptoms including pain caused by general compression or irritation of one of five spinal nerve roots of each sciatic nerve): 2 people, 2.99%
Burkitt Lymphoma (cancer of the lymphatic system): 2 people, 2.99%
Dyslipidaemia (abnormal amount of lipids): 2 people, 2.99%

* Approximation only. Some reports may have incomplete information.

Do you take Cytarabine and have Hepatitis acute?

- Check whether Hepatitis acute is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cytarabine:

Cytarabine (65,358 reports)

Hepatitis acute treatments and more:

Hepatitis acute (7,695 reports)

Browse all side effects of Cytarabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis acute:

Hepatitis acute (596 drugs)

Browse all the conditions that are associated with Hepatitis acute:

Hepatitis acute (877 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cytarabine (the active ingredients of Cytarabine) and Cytarabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.